Stay updated on Cadonilimab & Regorafenib Combo in Biliary Tumours Clinical Trial
Sign up to get notified when there's something new on the Cadonilimab & Regorafenib Combo in Biliary Tumours Clinical Trial page.

Latest updates to the Cadonilimab & Regorafenib Combo in Biliary Tumours Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded site revision v3.4.2 to the history and removed an older funding notice and revision (v3.4.1). These edits affect display metadata rather than the trial record data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check20 days agoChange DetectedAdded a site-wide funding notice and updated the page version to v3.4.1. The previous version v3.4.0 was removed.SummaryDifference0.9%

- Check28 days agoChange DetectedUI changes add a Show glossary option, color-coded highlights for record changes, and a revision tag showing v3.4.0 (with No FEAR Act Data labeling updates). No substantive study content or functionality was altered.SummaryDifference1%

- Check42 days agoChange DetectedRevision history shows a new entry for version v3.3.4 and removal of v3.3.3, indicating an administrative update to the page's history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Revision: v3.3.3 notice and removed the HHS Vulnerability Disclosure and Revision: v3.3.2 notes from the footer.SummaryDifference0.2%

- Check85 days agoChange DetectedA new revision (v3.3.2) was added to the history. It includes the last known status (Verified, Unknown status) and sponsor location Tianjin Medical University Cancer Institute and Hospital as of 2022-11.SummaryDifference1%

Stay in the know with updates to Cadonilimab & Regorafenib Combo in Biliary Tumours Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cadonilimab & Regorafenib Combo in Biliary Tumours Clinical Trial page.